Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.6% – Time to Sell?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) traded down 4.6% during trading on Thursday . The company traded as low as $21.90 and last traded at $21.63. 10,387 shares traded hands during mid-day trading, a decline of 97% from the average session volume of 310,105 shares. The stock had previously closed at $22.66.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on DNTH shares. TD Cowen started coverage on Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating on the stock. Oppenheimer lifted their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $46.43.

Dianthus Therapeutics Trading Down 4.8 %

The business’s fifty day moving average price is $23.16 and its 200 day moving average price is $26.23.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. As a group, research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. American Century Companies Inc. lifted its stake in shares of Dianthus Therapeutics by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock worth $788,000 after acquiring an additional 8,473 shares during the period. Point72 DIFC Ltd acquired a new stake in Dianthus Therapeutics during the 2nd quarter valued at $334,000. The Manufacturers Life Insurance Company purchased a new stake in Dianthus Therapeutics in the 2nd quarter worth about $236,000. SG Americas Securities LLC boosted its holdings in shares of Dianthus Therapeutics by 104.0% during the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after purchasing an additional 4,506 shares during the period. Finally, Quest Partners LLC boosted its stake in shares of Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after buying an additional 1,124 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.